These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Glycyrrhizin and isoliquiritigenin suppress the LPS sensor toll-like receptor 4/MD-2 complex signaling in a different manner. Honda H; Nagai Y; Matsunaga T; Saitoh S; Akashi-Takamura S; Hayashi H; Fujii I; Miyake K; Muraguchi A; Takatsu K J Leukoc Biol; 2012 Jun; 91(6):967-76. PubMed ID: 22422925 [TBL] [Abstract][Full Text] [Related]
43. The interplay between Angiotensin II, TLR4 and hypertension. Biancardi VC; Bomfim GF; Reis WL; Al-Gassimi S; Nunes KP Pharmacol Res; 2017 Jun; 120():88-96. PubMed ID: 28330785 [TBL] [Abstract][Full Text] [Related]
44. Research Progress of Mechanisms and Drug Therapy For Atherosclerosis on Toll-Like Receptor Pathway. Yin QY; Zhao B; Qiu YY; Fei YX; Hu YH; Li YM J Cardiovasc Pharmacol; 2019 Nov; 74(5):379-388. PubMed ID: 31730559 [TBL] [Abstract][Full Text] [Related]
45. Psoriasis: can statins play a dual role? Rajpara AN; Goldner R; Gaspari A Dermatol Online J; 2010 Feb; 16(2):2. PubMed ID: 20178698 [TBL] [Abstract][Full Text] [Related]
46. Quercetin regulates oxidized LDL induced inflammatory changes in human PBMCs by modulating the TLR-NF-κB signaling pathway. Bhaskar S; Shalini V; Helen A Immunobiology; 2011 Mar; 216(3):367-73. PubMed ID: 20828867 [TBL] [Abstract][Full Text] [Related]
47. The role of acetylation in TLR4-mediated innate immune responses. Hu X; Yu Y; Eugene Chin Y; Xia Q Immunol Cell Biol; 2013; 91(10):611-4. PubMed ID: 24100389 [TBL] [Abstract][Full Text] [Related]
49. Inhibition of homodimerization of toll-like receptor 4 by 4-oxo-4-(2-oxo-oxazolidin-3-yl)-but-2-enoic acid ethyl ester. Park SJ; Kang SH; Kang YK; Eom YB; Koh KO; Kim DY; Youn HS Int Immunopharmacol; 2011 Jan; 11(1):19-22. PubMed ID: 20939996 [TBL] [Abstract][Full Text] [Related]
50. Transcriptome assessment reveals a dominant role for TLR4 in the activation of human monocytes by the alarmin MRP8. Fassl SK; Austermann J; Papantonopoulou O; Riemenschneider M; Xue J; Bertheloot D; Freise N; Spiekermann C; Witten A; Viemann D; Kirschnek S; Stoll M; Latz E; Schultze JL; Roth J; Vogl T J Immunol; 2015 Jan; 194(2):575-83. PubMed ID: 25505274 [TBL] [Abstract][Full Text] [Related]
51. The molecular basis of vulnerable plaque: potential therapeutic role for immunomodulation. Wilensky RL; Hamamdzic D Curr Opin Cardiol; 2007 Nov; 22(6):545-51. PubMed ID: 17921743 [TBL] [Abstract][Full Text] [Related]
52. Effect of interleukin 1β inhibition in cardiovascular disease. Qamar A; Rader DJ Curr Opin Lipidol; 2012 Dec; 23(6):548-53. PubMed ID: 23069985 [TBL] [Abstract][Full Text] [Related]
53. Renin-angiotensin system antagonism and lipid-lowering therapy in cardiovascular risk management. Chiong JR; Miller AB J Renin Angiotensin Aldosterone Syst; 2002 Jun; 3(2):96-102. PubMed ID: 12228849 [TBL] [Abstract][Full Text] [Related]
54. Role of Toll-like receptor 4/NF-kappaB pathway in monocyte-endothelial adhesion induced by low shear stress and ox-LDL. Yang QW; Mou L; Lv FL; Wang JZ; Wang L; Zhou HJ; Gao D Biorheology; 2005; 42(3):225-36. PubMed ID: 15894821 [TBL] [Abstract][Full Text] [Related]
56. Anti-inflammatory effects of genistein via suppression of the toll-like receptor 4-mediated signaling pathway in lipopolysaccharide-stimulated BV2 microglia. Jeong JW; Lee HH; Han MH; Kim GY; Kim WJ; Choi YH Chem Biol Interact; 2014 Apr; 212():30-9. PubMed ID: 24491678 [TBL] [Abstract][Full Text] [Related]
57. The role of toll-like receptor 4 (TLR4) in cancer progression: A possible therapeutic target? Kashani B; Zandi Z; Pourbagheri-Sigaroodi A; Bashash D; Ghaffari SH J Cell Physiol; 2021 Jun; 236(6):4121-4137. PubMed ID: 33230811 [TBL] [Abstract][Full Text] [Related]
58. [The role of TLR4 receptor in development of inflammation and carcinogenesis in ulcerative colitis and pharmacotherapy of this disorder]. Szumilas D; Krysiak R; Okopień B Wiad Lek; 2013; 66(1):3-9. PubMed ID: 23905422 [TBL] [Abstract][Full Text] [Related]
59. Toll-like receptor 4 regulates lipopolysaccharide-induced inflammation and lactation insufficiency in a mouse model of mastitis. Glynn DJ; Hutchinson MR; Ingman WV Biol Reprod; 2014 May; 90(5):91. PubMed ID: 24671877 [TBL] [Abstract][Full Text] [Related]
60. Targeting toll-like receptor 4 signalling pathways: can therapeutics pay the toll for hypertension? Nunes KP; de Oliveira AA; Mowry FE; Biancardi VC Br J Pharmacol; 2019 Jun; 176(12):1864-1879. PubMed ID: 29981161 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]